Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Abstract
Because CT of spinal extraarachnoid metrizamide collections may be misleading, we reviewed the postmetrizamide CT scans of 425 patients in order to characterize the appearance of subdural or epidural metrizamide. Eight patients were found to have extraarachnoid metrizamide contrast collections. In all patients, both the subarachnoid space and the extraarachnoid collection were opacified with metrizamide. In seven patients, a subdural collection of metrizamide created a mass upon the opacified subarachnoid space. Three of these subdural collections were less dense than the opacified subarachnoid compartment and simulated soft-tissue disease, including tumor and an arteriovenous malformation. The hypodense collections are probably a result of leakage of metrizamide and cerebrospinal fluid through the spinal needle defect. CT clues for diagnosing these potentially misleading subdural collections include preservation of the normal dural and epidural interface, identification of small islands of metrizamide within a suspected soft-tissue "mass," the presence of concomitant epidural contrast material collections, and the absence of adjacent vertebral-body destruction.
View details for Web of Science ID A1986D685000029
View details for PubMedID 3488660